Author

Samuel Tanner Pasco

CIC bioGUNEORCID 0000-0002-4276-4098Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Ana Ruiz-SáenziD· 1 shared Arkaitz CarracedoiD· 1 shared Danny HuylebroeckiD· 1 shared Laura Bozal‐BasterraiD· 1 shared Mark M. MoasseriD· 1 shared Roos VinckeniD· 1 shared Veronica SteriiD· 1 shared Wilfred F. J. van IJckeniD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

8 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Ana Ruiz-SáenzORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Metabolic Alterations driven by PFKFB3 upregulation confer Resistance to Trastuzumab in HER2-Positive Breast Cancer.

Roos Vincken, Samuel Tanner Pasco, Veronica Steri, Laura Bozal‐Basterra, Wilfred F. J. van IJcken, Arkaitz Carracedo, Danny Huylebroeck, Mark M. Moasser, Ana Ruiz-Sáenz

This study identifies PFKFB3 upregulation as a driver of trastuzumab resistance in HER2+ breast cancer through metabolic rewiring and reduced ADCC, with clinical correlations to poor survival.

Biomedicine & Pharmacotherapy · Jan 1, 2026Peer-reviewedCancer Biology